Post
Moleculin doses first patients in Phase II portion of AML Annamycin combo study
Moleculin Biotech has dosed the first subjects in the Phase II portion of a Phase Ib/II trial evaluating the company’s …
Syndax leukaemia drug hits endpoint goals ahead of planned new drug application
Clinical-stage biopharmaceutical company, Syndax, has announced that it has met one of its goals as part of a Phase I/II …
Pipeline Moves: Advancement prospects plunge for myelodysplastic syndrome drug after trial termination
This week on Pipeline Moves, we kickoff by looking at the terminations of a Phase II trial in myelodysplastic syndrome …
Novartis eyes accelerated FDA approval for iptacopan across multiple indications
Novartis has announced positive interim results for iptacopan from the Phase III Applause-IgAN study showing significant proteinuria reduction in patients …
AbbVie’s venetoclax fails Phase III myeloma trial
AbbVie reported negative results from a Phase III CANOVA trial investigating venetoclax in patients with relapsed or refractory multiple myeloma. The …
Phase III results boost datopotomab deruxtecan’s potential in breast cancer
On 22 September, AstraZeneca announced positive interim data for the Phase III TROPION-Breast01 trial evaluating Daiichi Sankyo and AstraZeneca’s datopotomab …
Signal: Philips knew about ventilator defects for years before recall
Multinational electronics and medical device manufacturer Philips knew for over a decade about the defects in its respiratory devices before …
Limited innovation in the late-stage pipeline for insomnia
Insomnia is the most common sleep disorder, characterised by patient-reported difficulty with sleep initiation and/or sleep maintenance. According to the …
Regeneron’s linvoseltamab shows early and durable response in pre-treated MM
Regeneron Pharmaceuticals has presented Phase II data for linvoseltamab in patients with relapsed/refractory (r/r) multiple myeloma (MM) who have received …
Q&A: ‘Trial failure due to recruitment is a thing of the past thanks to AI’
One pain point for sponsors is trial termination due to lack of recruitment, partially a result of recruiting the wrong …
PercAssist implants first patient with extravascular cardiac assistance device
PercAssist has completed its first patient case in its First-in-Human clinical study investigating its Percutaneous Synchronised Cardiac Assist (PSCA) device …
Janssen’s NSCLC combo therapy meets primary endpoint in Phase III trial
The Janssen Pharmaceutical Companies of Johnson & Johnson has reported that the Phase III MARIPOSA clinical trial of Rybrevant (amivantamab-vmjw) …
ImmunoGenesis begins participant dosing in trial of IMGS‑001
ImmunoGenesis has dosed the first participant in its Phase Ia/Ib clinical trial of IMGS-001 for the treatment of relapsed or refractory advanced …
Aleta aims for pivotal US trial with CAR T-cell engager
Aleta Biotherapeutics is working to initiate a potentially registrational trial in the US for its CAR T-cell therapy engager (CTE) …
Ascletis reports positive data from Phase IIb hepatitis B therapy trial
Ascletis Pharma has reported positive interim findings from an expansion cohort of the Phase IIb clinical trial of ASC22 (Envafolimab) being analysed …